IRulya Therapeutics IRLA Director · filings 2026 to 2026
No transactions in the filings read; Form 144 notices are listed above.
Person · CIK 1930805
John Drayton Wise
Director at IRulya Therapeutics; Chief Commercial Officer at INSMED
Sold on Form 4$3M
Noticed on Form 144$7.2M
Bought on Form 4$0
Companies2
Holdings now
As reported after the latest Form 3, 4 or 5 at each company.
How these figures work
Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.
| Company | Security | Held | Shares or units | As of |
|---|---|---|---|---|
| INSMED INSM | Common Stock | Directly | 133,015 | Feb 7, 2025 · Filing · EDGAR |
| INSMED INSM | Stock Option (right to buy) | Directly | 103,984 | Jan 3, 2024 · Filing · EDGAR |
| INSMED INSM | Stock Option (right to buy) exercise $65.72, expires Jan 8, 2035, into Common Stock | Directly | 31,930 | Jan 8, 2025 · Filing · EDGAR |
Sold and noticed by quarter
Sold (Form 4) Noticed (Form 144) Bought (Form 4)
Quarterly totals as a table
| Quarter | Sold (Form 4) | Noticed (Form 144) |
|---|---|---|
| Q2 2025 | — | $4.2M |
| Q1 2025 | $1.5M | $1.5M |
| Q2 2024 | $521K | $520K |
| Q1 2024 | $674K | $741K |
| Q2 2023 | $117K | $233K |
| Q1 2023 | $37K | Not machine-readable |
| Q4 2022 | $135K | Not machine-readable |
| Q3 2022 | $7K | Not machine-readable |
Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.
Planned sales (Form 144) and the sales that followed
Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.
How we match
A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.
| Notice date | Noticed | Planned sale | Outcome | Links |
|---|---|---|---|---|
| INSMED INSM · Merrill Lynch · 10b5-1 plan adopted Feb 27, 2024 · 3 notices | ||||
| Jun 23, 2025 | 20,000 · ~$2.1M | Jun 23, 2025 | Not sold within 90 days | Filing · EDGAR |
| May 20, 2025 | 7,000 · ~$472K | May 20, 2025 | Not sold within 90 days | Filing · EDGAR |
| Jan 7, 2025 | 10,000 · ~$659K | Jan 7, 2025 | Sold as noticed Sold 10,000 at $65.98 on Jan 7 · $660K Form 4 | Filing · EDGAR |
| INSMED INSM · Merrill Lynch · No 10b5-1 plan stated · 13 notices | ||||
| Jun 13, 2025 | 4,486 · ~$440K | Jun 13, 2025 | Not sold within 90 days | Filing · EDGAR |
| Jun 3, 2025 | 1,860 · ~$133K | Jun 3, 2025 | Not sold within 90 days | Filing · EDGAR |
| May 29, 2025 | 6,691 · ~$446K | May 29, 2025 | Not sold within 90 days | Filing · EDGAR |
| May 28, 2025 | 3,431 · ~$233K | May 28, 2025 | Not sold within 90 days | Filing · EDGAR |
| May 14, 2025 | 401 · ~$26K | May 14, 2025 | Not sold within 90 days | Filing · EDGAR |
| May 13, 2025 | 4,610 · ~$313K | May 13, 2025 | Not sold within 90 days | Filing · EDGAR |
| Feb 6, 2025 | 8,000 · ~$647K | Feb 6, 2025 | Partly sold Sold 7,910 at $80.90 on Feb 6 · $640K likely match Form 4 | Filing · EDGAR |
| Jan 10, 2025 | 287 · ~$19K | Jan 10, 2025 | Sold as noticed Sold 287 at $65.40 on Jan 10 · $19K Form 4 | Filing · EDGAR |
| Jan 8, 2025 | 392 · ~$26K | Jan 8, 2025 | Sold as noticed Sold 392 at $66.21 on Jan 8 · $26K Form 4 | Filing · EDGAR |
| Jan 7, 2025 | 2,908 · ~$192K | Jan 7, 2025 | Sold as noticed Sold 2,918 in 2 sales, Jan 7 to Feb 7 · $192K Form 4 (1) · Form 4 (2) | Filing · EDGAR |
| May 28, 2024 | 1,602 · ~$78K | May 28, 2024 | Sold as noticed Sold 1,602 at $48.95 on May 28 · $78K Form 4 | Filing · EDGAR |
| May 14, 2024 | 5,088 · ~$130K | May 14, 2024 | Sold as noticed Sold 5,088 at $25.47 on May 14 · $130K Form 4 | Filing · EDGAR |
| Jan 5, 2024 | 5,347 · ~$156K | Jan 5, 2024 | Partly sold Sold 3,028 in 2 sales, Jan 5 to Jan 9 · $88K likely match Form 4 (1) · Form 4 (2) | Filing · EDGAR |
| INSMED INSM · Merrill Lynch · 10b5-1 plan adopted Mar 7, 2023 · 3 notices | ||||
| May 28, 2024 | 6,250 · ~$312K | May 28, 2024 | Sold as noticed Sold 6,250 at $50.00 on May 28 · $313K Form 4 | Filing · EDGAR |
| Jan 3, 2024 | 20,071 · ~$585K | Jan 3, 2024 | Sold as noticed Sold 20,071 at $29.19 on Jan 3 · $586K Form 4 | Filing · EDGAR |
| May 15, 2023 | 12,043 · ~$233K | May 15, 2023 | Partly sold Sold 6,253 in 4 sales, May 15 to May 25 · $117K likely match Form 4 (1) · Form 4 (2) | Filing · EDGAR |
| Sales without a matching Form 144 · 4 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt. | ||||
| — | — | — | Notice not machine-readable INSMED (INSM): Sold 779 at $17.96 on Jan 10, 2023 · $14K | Filing · EDGAR |
| — | — | — | Notice not machine-readable INSMED (INSM): Sold 1,160 at $19.74 on Jan 5, 2023 · $23K | Filing · EDGAR |
| — | — | — | Notice not machine-readable INSMED (INSM): Sold 7,154 at $18.84 on Nov 22, 2022 · $135K | Filing · EDGAR |
| — | — | — | Notice not machine-readable INSMED (INSM): Sold 258 at $27.79 on Aug 10, 2022 · $7K | Filing · EDGAR |
Every transaction, by company
Each Form 3, 4 and 5 transaction in plain words, newest first.
How these figures work
Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.
INSMED INSM Chief Commercial Officer · filings 2022 to 2025 · sold $3M · $7.2M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 7, 2025 | Open-market or private sale | −10 | $78.91 | $789 | 133,015 direct | Filing · EDGAR |
| Feb 6, 2025 | Open-market or private sale | −7,910 | $80.90 | $640K | 133,025 direct | Filing · EDGAR |
| Feb 5, 2025 | Grant or award from the company | +15,373 | 140,935 direct | Filing · EDGAR | ||
| Jan 10, 2025 | Sale under a 10b5-1 plan | −287 | $65.40 | $19K | 125,562 direct | Filing · EDGAR |
| Jan 8, 2025 | Sale under a 10b5-1 plan | −392 | $66.21 | $26K | 119,192 direct | Filing · EDGAR |
| Jan 8, 2025 | Grant or award from the company | +6,657 | 125,849 direct | Filing · EDGAR | ||
| Jan 8, 2025 | Grant or award from the company Stock Option (right to buy) | +31,930 | 31,930 direct | Filing · EDGAR | ||
| Jan 7, 2025 | Option or RSU exercised or converted | +10,000 | $16.07 | $161K | 132,492 direct | Filing · EDGAR |
| Jan 7, 2025 | Sale under a 10b5-1 plan | −10,000 | $65.98 | $660K | 122,492 direct | Filing · EDGAR |
| Jan 7, 2025 | Sale under a 10b5-1 plan | −2,908 | $65.87 | $192K | 119,584 direct | Filing · EDGAR |
| Jan 7, 2025 | Option or RSU exercised or converted Stock Option (right to buy) | −10,000 | 0 direct | Filing · EDGAR | ||
| May 28, 2024 | Sale under a 10b5-1 plan | −1,602 | $48.95 | $78K | 121,657 direct | Filing · EDGAR |
| May 28, 2024 | Option or RSU exercised or converted | +6,250 | $12.58 | $79K | 127,907 direct | Filing · EDGAR |
| May 28, 2024 | Sale under a 10b5-1 plan | −6,250 | $50.00 | $313K | 121,657 direct | Filing · EDGAR |
| May 28, 2024 | Option or RSU exercised or converted Stock Option (right to buy) | −6,250 | 0 direct | Filing · EDGAR | ||
| May 14, 2024 | Open-market or private sale | −5,088 | $25.47 | $130K | 123,259 direct | Filing · EDGAR |
| May 13, 2024 | Grant or award from the company | +14,518 | 128,347 direct | Filing · EDGAR | ||
| May 13, 2024 | Grant or award from the company Stock Option (right to buy) | +71,160 | 71,160 direct | Filing · EDGAR | ||
| Jan 9, 2024 | Open-market or private sale | −1,861 | $28.78 | $54K | 113,829 direct | Filing · EDGAR |
| Jan 5, 2024 | Sale under a 10b5-1 plan | −1,167 | $29.32 | $34K | 115,690 direct | Filing · EDGAR |
| Jan 4, 2024 | Grant or award from the company | +12,873 | 116,857 direct | Filing · EDGAR | ||
| Jan 4, 2024 | Grant or award from the company Stock Option (right to buy) | +63,560 | 63,560 direct | Filing · EDGAR | ||
| Jan 3, 2024 | Option or RSU exercised or converted | +20,071 | $19.11 | $384K | 124,055 direct | Filing · EDGAR |
| Jan 3, 2024 | Sale under a 10b5-1 plan | −20,071 | $29.19 | $586K | 103,984 direct | Filing · EDGAR |
| Jan 3, 2024 | Option or RSU exercised or converted Stock Option (right to buy) | −20,071 | 0 direct | Filing · EDGAR | ||
| May 25, 2023 | Open-market or private sale | −3,366 | $18.95 | $64K | 102,681 direct | Filing · EDGAR |
| May 17, 2023 | Open-market or private sale | −1,913 | $18.17 | $35K | 106,047 direct | Filing · EDGAR |
| May 16, 2023 | Open-market or private sale | −381 | $18.44 | $7K | 107,960 direct | Filing · EDGAR |
| May 15, 2023 | Open-market or private sale | −593 | $19.29 | $11K | 108,341 direct | Filing · EDGAR |
| May 11, 2023 | Grant or award from the company | +31,662 | 108,934 direct | Filing · EDGAR | ||
| May 11, 2023 | Grant or award from the company Stock Option (right to buy) | +146,220 | 146,220 direct | Filing · EDGAR | ||
| Jan 10, 2023 | Open-market or private sale | −779 | $17.96 | $14K | 77,272 direct | Filing · EDGAR |
| Jan 5, 2023 | Open-market or private sale | −1,160 | $19.74 | $23K | 70,453 direct | Filing · EDGAR |
| Jan 5, 2023 | Grant or award from the company | +7,598 | 78,051 direct | Filing · EDGAR | ||
| Jan 5, 2023 | Grant or award from the company Stock Option (right to buy) | +34,860 | 34,860 direct | Filing · EDGAR | ||
| Nov 22, 2022 | Open-market or private sale | −7,154 | $18.84 | $135K | 71,613 direct | Filing · EDGAR |
| Aug 10, 2022 | Open-market or private sale | −258 | $27.79 | $7K | 78,767 direct | Filing · EDGAR |
| May 23, 2022 | Grant or award from the company | +26,236 | 78,137 direct | Filing · EDGAR | ||
| May 23, 2022 | Grant or award from the company Stock Option (right to buy) | +164,580 | 164,580 direct | Filing · EDGAR |
All 35 Forms 3, 4, 5 and 144
| Filed | Form | Company | Links |
|---|---|---|---|
| Oct 19, 2026 | Form 3 | IRulya Therapeutics IRLA | Filing · EDGAR |
| Jun 23, 2025 | Form 144 | INSMED INSM | Filing · EDGAR |
| Jun 13, 2025 | Form 144 | INSMED INSM | Filing · EDGAR |
| Jun 3, 2025 | Form 144 | INSMED INSM | Filing · EDGAR |
| May 29, 2025 | Form 144 | INSMED INSM | Filing · EDGAR |
| May 28, 2025 | Form 144 | INSMED INSM | Filing · EDGAR |
| May 20, 2025 | Form 144 | INSMED INSM | Filing · EDGAR |
| May 14, 2025 | Form 144 | INSMED INSM | Filing · EDGAR |
| May 13, 2025 | Form 144 | INSMED INSM | Filing · EDGAR |
| Feb 7, 2025 | Form 4 | INSMED INSM | Filing · EDGAR |
| Feb 6, 2025 | Form 144 | INSMED INSM | Filing · EDGAR |
| Jan 10, 2025 | Form 144 | INSMED INSM | Filing · EDGAR |
| Jan 10, 2025 | Form 4 | INSMED INSM | Filing · EDGAR |
| Jan 8, 2025 | Form 144 | INSMED INSM | Filing · EDGAR |
| Jan 7, 2025 | Form 144 | INSMED INSM | Filing · EDGAR |
| Jan 7, 2025 | Form 144 | INSMED INSM | Filing · EDGAR |
| May 30, 2024 | Form 4 | INSMED INSM | Filing · EDGAR |
| May 28, 2024 | Form 144 | INSMED INSM | Filing · EDGAR |
| May 28, 2024 | Form 144 | INSMED INSM | Filing · EDGAR |
| May 15, 2024 | Form 4 | INSMED INSM | Filing · EDGAR |
| May 14, 2024 | Form 144 | INSMED INSM | Filing · EDGAR |
| Jan 11, 2024 | Form 4 | INSMED INSM | Filing · EDGAR |
| Jan 5, 2024 | Form 144 | INSMED INSM | Filing · EDGAR |
| Jan 5, 2024 | Form 4 | INSMED INSM | Filing · EDGAR |
| Jan 3, 2024 | Form 144 | INSMED INSM | Filing · EDGAR |
| May 26, 2023 | Form 4 | INSMED INSM | Filing · EDGAR |
| May 17, 2023 | Form 4 | INSMED INSM | Filing · EDGAR |
| May 15, 2023 | Form 144 | INSMED INSM | Filing · EDGAR |
| May 15, 2023 | Form 4 | INSMED INSM | Filing · EDGAR |
| Jan 12, 2023 | Form 4 | INSMED INSM | Filing · EDGAR |
| Jan 6, 2023 | Form 4 | INSMED INSM | Filing · EDGAR |
| Nov 22, 2022 | Form 4 | INSMED INSM | Filing · EDGAR |
| Aug 12, 2022 | Form 4 | INSMED INSM | Filing · EDGAR |
| May 25, 2022 | Form 4 | INSMED INSM | Filing · EDGAR |
| May 25, 2022 | Form 3 | INSMED INSM | Filing · EDGAR |
Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.